| Attention deficit hyperactivity disorder
Qelbree vs QuilliChew ER
Side-by-side clinical, coverage, and cost comparison for attention deficit hyperactivity disorder.Deep comparison between: Qelbree vs Quillichew Er with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQuillichew Er has a higher rate of injection site reactions vs Qelbree based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Quillichew Er but not Qelbree, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qelbree
Quillichew Er
At A Glance
Oral
Once daily
Selective norepinephrine reuptake inhibitor
Oral
Daily
CNS stimulant
Indications
- Attention deficit hyperactivity disorder
- Attention deficit hyperactivity disorder
Dosing
Attention deficit hyperactivity disorder (ages 6-11) 100 mg orally once daily; may titrate in increments of 100 mg weekly to a maximum of 400 mg once daily.
Attention deficit hyperactivity disorder (ages 12-17) 200 mg orally once daily; may titrate after 1 week by 200 mg to a maximum of 400 mg once daily.
Attention deficit hyperactivity disorder (adults) 200 mg orally once daily; may titrate in increments of 200 mg weekly to a maximum of 600 mg once daily.
Severe renal impairment 100 mg once daily; titrate in weekly increments of 50-100 mg to a maximum of 200 mg once daily.
Attention deficit hyperactivity disorder Starting dose 20 mg once daily orally in the morning for patients 6 years and above; titrate weekly in increments of 10 mg, 15 mg, or 20 mg; doses above 60 mg/day have not been studied and are not recommended.
Contraindications
- Concomitant treatment with monoamine oxidase inhibitors (MAOI), or within 14 days following discontinuing an MAOI, due to increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range
- Hypersensitivity to methylphenidate or other components of QuilliChew ER
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days following MAOI discontinuation
Adverse Reactions
Most common (>=5%) - Pediatric (ages 6-17) Somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, irritability
Most common (>=5%) - Adults Insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, constipation
Serious Suicidal thoughts and behaviors, blood pressure and heart rate increases, activation of mania or hypomania, somnolence and fatigue
Most common (>=2%) Decreased appetite, aggression, emotional poverty, nausea, headache, weight decreased
Postmarketing Pancytopenia, thrombocytopenia, angina pectoris, severe hepatocellular injury, angioedema, anaphylactic reactions, convulsion, dyskinesia, serotonin syndrome, hallucination, mania, priapism, rhabdomyolysis, Raynaud's phenomenon
Pharmacology
Viloxazine is a selective norepinephrine reuptake inhibitor that inhibits the norepinephrine transporter and exhibits partial agonist activity at the serotonin 5-HT2C receptor; its mechanism of action in ADHD is thought to be through inhibiting norepinephrine reuptake.
Methylphenidate is a CNS stimulant that blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space; the d-isomer is more pharmacologically active than the l-isomer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qelbree
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Quillichew Er
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Qelbree
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Quillichew Er
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qelbree
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Quillichew Er
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qelbree.
No savings programs available for Quillichew Er.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QelbreeView full Qelbree profile
Quillichew ErView full Quillichew Er profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.